What are the comparative efficacy and safety profiles of hydroxychloroquine and cyclophosphamide in women in their 40s over a 6-month treatment period?
Abstract
While evidence suggests that hydroxychloroquine may be associated with a favorable safety outcome compared to cyclophosphamide in the context of SLE patients with COVID-19, direct comparative data on efficacy and safety over a standard treatment period remains limited.
Fields of Study & Subjects
Systemic Lupus Erythematosus Research
COVID-19 Clinical Research Studies
Systemic Sclerosis and Related Diseases
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 9 January 2026